Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

Schnitzler, F.; Fidder, H.; Ferrante, M.; Noman, M.; Arijs, I.; Van Assche, G.; Hoffman, I.; Van Steen, K.; Vermeire, S.; Rutgeerts, P.
April 2009
Gut;Apr2009, Vol. 58 Issue 4, p492
Academic Journal
Background and aims: This observational study assessed the long-term clinical benefit of infliximab (IFX) in 614 consecutive patients with Crohn's disease (CD) from a single centre during a median follow-up of 55 months (interquartile range (IQR) 27-83). Methods: The primary analysis looked at the proportion of patients with initial response to IFX who had sustained clinical benefit at the end of follow-up. The long-term effects of IFX on the course of CD as reflected by the rate of surgery and hospitalisations and need for corticosteroids were also analysed. Results: 10.9% of patients were primary non-responders to IFX. Sustained benefit was observed in 347 of the 547 patients (63.4%) receiving long-term treatment. In 68.3% of these, treatment with IFX was ongoing and in 31.7% IFX was stopped, with the patient being in remission. Seventy patients (12.8%) had to stop IFX due to side effects and 118 (21.6%) due to loss of response. Although the yearly drop-out rates of IFX in patients with episodic (10.7%) and scheduled treatment (7.1%) were similar, the need for hospitalisations and surgery decreased less in the episodic than in the scheduled group. Steroid discontinuation also occurred in a higher proportion of patients in the scheduled group than in the episodic group. Conclusions: In this large real-life cohort of patients with CD, long-term treatment with IFX was very efficacious to maintain improvement during a median follow-up of almost 5 years and changed disease outcome by decreasing the rate of hospitalisations and surgery.


Related Articles

  • New Relief for Crohn's Disease. Harrar, Sari; Metcalf, Eric // Prevention;Mar2002, Vol. 54 Issue 3, p155 

    Reports that the steroid drug budesonide is effective in treating Crohn's disease flare-ups and has fewer side effects than prednisone, the conventional therapy.

  • Controversies in the treatment of Crohn's disease: The case for an accelerated step-up treatment approach. Shergill, Amandeep K.; Terdiman, Jonathan P.; Wexner, Steven D.; Duchmann, Rainer J. // World Journal of Gastroenterology;5/7/2008, Vol. 14 Issue 17, p2670 

    The ideal treatment strategy for Crohn's disease (CD) remains uncertain, as does the optimal endpoint of therapy. Top-down versus step-up describes two different approaches: early use of immunomodulators and biological agents in the former versus initial treatment with steroids in the latter,...

  • Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Cornillie, Freddy; Hanauer, Stephen B.; Diamond, Robert H.; Jianping Wang; Tang, Kezhen L.; Zhenhua Xu; Rutgeerts, Paul; Vermeire, Séverine // Gut;Nov2014, Vol. 63 Issue 11, p1721 

    Background: Serum infliximab trough levels correlate with efficacy; dose escalation is often beneficial in patients with Crohn's disease who stop responding to infliximab treatment. Objective: To carry out a post hoc analysis of A Crohn's Disease Clinical Trial Evaluating Infliximab in a New...

  • Phase II antisense sets Crohn disease precedents. Mullard, Asher // Nature Reviews Drug Discovery;May2015, Vol. 14 Issue 5, p301 

    The article discusses the Phase II clinical trial data of mongersen, an experimental drug for the treatment of Crohn disease from pharmaceutical company Celgene, and mentioned the statement of gastroenterologist Séverine Vermeire on the clinical effects of the drug.

  • Corticosteroids for Crohn's Disease. Singleton, John W. // Annals of Internal Medicine;Jun79, Vol. 90 Issue 6, p983 

    Editorial. Focuses on the drug therapy for Crohn's disease. Information on steroids used for the treatment of active symptomatic Crohn's disease; Role of prophylactic steroids in quiescent disease after complete surgical extirpation of the disease; Discussion on the safety of withdrawing from...

  • Hospitalisations and surgery in Crohn's disease. Bernstein, Charles N.; Loftus, Jr. Edward V.; Siew, C. Ng.; Lakatos, Peter L.; Moum, Bjorn // Gut;Apr2012, Vol. 61 Issue 4, p622 

    Hospitalisation and surgery are considered to be markers of more severe disease in Crohn's disease. These are costly events and limiting these costs has emerged as one rationale for the cost of expensive biologic therapies. The authors sought to review the most recent international literature to...

  • Economic implications of biological therapy for Crohn's disease. Petryszyn, Paweł W.; Paradowski, Leszek // Gastroenterology Review / Przeglad Gastroenterologiczny;2015, Vol. 10 Issue 4, p197 

    In the early 90s American authors estimated that if a theoretical new drug was introduced that was capable of changing the natural course of the disease and reducing direct non-drug medical costs (including hospitalisation and surgery) by 20%, despite doubling the overall drugs bill, there would...

  • The natural history of Crohn's disease: who holds the crystal ball? Assche, Gert Van // Gut;Aug2012, Vol. 61 Issue 8, p1106 

    The author discusses the patients suffering from inflammatory disease phenotype and the biological therapy for Crohn's disease. He informs that patients with perianal disease may require several courses of steroids and surgery for controlling the disease. Several patients suffer with permanent...

  • Long-term outcome after ileocecal resection for Crohn's... Kim, Nam K.; Senagore, Anthony J. // American Surgeon;Jul1997, Vol. 63 Issue 7, p627 

    Reports the long-term clinical outcome of patients undergoing ileocecal resection for Crohn's disease between 1970 and 1993. Most common site of Crohn's disease; Methods used in the study; Indications for initial resection of ileocecal Crohn's disease; Postoperative complications; Recurrence of...


Read the Article


Sign out of this library

Other Topics